US venture capital investment in biotechnology companies fell during the second quarter, but remained near recent record-breaking levels as investors continued to support larger funding rounds for some biotechnology startups – a trend that's ongoing in the third quarter with Series A rounds totaling $57m for Oncorus Inc. and $55m for Fulcrum Therapeutics.
A hundred biotech companies raised $1.7bn during the second quarter of 2016 compared with 127 that raised $2.1bn during the...